Moreadith Randall, Chief Scientific Officer, has demonstrated a pronounced selling bias in recent transactions involving SER stock, with no recorded purchases in the past year. Since December 2025, Randall has executed 12 sales totaling approximately $111,971, with the largest single transaction occurring on March 19, 2026, when shares worth $97,500 were sold. The transactions follow a consistent pattern, often paired with smaller sales labeled as "M" (likely market sales) on the same day—such as the March 23, 2026, sale of $18,567.90 alongside a $390 disposition. The selling activity has been steady, with multiple transactions in January and February 2026, including a $19,680.05 sale on February 2 and a $23,185.50 sale on January 28.
Randall’s trading history shows a clear divestment trend, with cumulative sales far outweighing any prior buying activity—total lifetime buys amount to just $15,210 compared to over $1.1 million in sales. The transactions suggest an ongoing reduction in SER holdings, with no recent acquisitions to offset the disposals. While the filings do not indicate the reasons behind the sales, the pattern reflects a sustained exit from positions in the biotech firm, particularly concentrated in early 2026. The absence of any buys during this period reinforces the directional bias toward liquidation rather than accumulation.
AI-assisted summary